Abstract
Lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutary coenzyme A reductase activity, is used to treat hypercholesteremia by inhibiting the synthesis of mevalonate. We report here, that Lovastatin can also be used in vitro to arrest mammalian cells in the G1 phase of the cell cycle. Lovastatin provides a simple method for obtaining large quantities of synchronous cells in most mammalian cells examined to date with minimal overall metabolic perturbations. Further-more, Lovastatin can be used for synchronizing normal as well as tumor cells at a specific phase of the cell cycle reversibly and without causing cytotoxicity. Cells arrested by Lovastatin can be released to enter the cell cycle synchronously by the addition of mevalonate. In some cell types synchrony can be followed for multiple cycles allowing the study of events that occur in mid to late cycles.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Terasima T, Tolmach LJ (1963). Growth and nucleic acid synthesis in synchronously dividing populations of HeLa cells. Exp Cell Res 30: 344–362.
Ashihara T, Baserga R (1979). Cell synchronization. Methods Enzymol 58: 248–262.
Kauffman MG, Noga SJ, Kelly TJ, Donnenberg AD (1990). Isolation of cell cycle fractions by counterflow centrifugal elutriation. Analytical Biochem 191: 41–46.
Lutz MP, Gaedicke G, Hartmann W (1992). Largescale cell separation by centrifugal elutriation. Analytical Biochem 200: 376–380.
Johnson RT, Downes CS, Meyn RE (1993). The synchronization of mammalian cells. In: P Fantes, R Brooks (eds), The cell cycle: A practical approach. New York: Oxford University Press, pp 1–23.
Rao PN, Johnson RT (1970). Mammalian cell fusion: Studies on the regulation of DNA synthesis and mitosis. Nature 225: 159–164.
Pedrali-Noy G, Spadari S, Miller-Faured A, Miller AO, Kruppa J, Koch G (1980). Synchronization of HeLa cell cultures by inhibition of DNA polymerase alpha with aphidicolin. Nuc Acids Res 82: 377–387.
D'Anna JA, Crissman HA, Jackson PJ, Tobey R (1985). Time-dependent changes in H1 content, H1 turnover, DNA elongation, and the survival of cells blocked in early S phase by hydroxyurea, aphidicolin, or 5-fluorodeoxyuridine. Biochemistry 24: 5020–5026.
Lambert WC, Studzinski GP (1967). Recovery from prolonged unbalanced growth induced in HeLa cells by high concentrations of thymidine. Cancer Res 27: 2364–2369.
Keyomarsi K, Sandoval L, Band V, Pardee AB (1991). Synchronization of tumor and normal cells from G1 to multiple cell cycles by Lovastatin. Cancer Res 51: 3602–3609.
Alberts AW, Chen J, Kuron G, et al. (1980). Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77: 3957–3961.
Endo A, Kuroda M, Tansawa K (1976). Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B, fungal metabolites having hypocholesterolemic activity. FEBS Lett 72: 323–326.
Larson RA, Chung J, Scanu AM, Yachnin S (1982). Neutrophils are required for the DNA synthetic response of human lymphocytes to mevalonic acid: Evidence suggesting that a nonsterol product of mevalonate is involved. Proc. Natl Acad Sci USA 79: 3028–3032.
Habenicht AJR, Glomset JA, Ross R (1980). Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 255: 5134–5140.
Maltese WA, Sheridan KM (1987). Isoprenylated proteins in cultured cells: Subcellular distribution and changes related to altered morphology and growth arrest induced by mevalonate deprivation. J Cell Physiol 133: 471–481.
Langan TJ, Volpe JJ (1987). Cell cycle-specific requirement for mevalonate, but not for cholesterol, for DNA synthesis in glial primary cultures. J Neurochem 49: 513–521.
Doyle JW, Kandutsch AA (1988). Requirement for mevalonate in cycling cells: Quantitative and temporal aspects. J Cell Physiol 137: 133–140.
Sinensky M, Logel J (1985). Defective macromolecule biosynthesis and cell-cycle progression in a mammalian cell starved for mevalonate. Proc Natl Acad Sci USA 82: 3257–3261.
Harrock DL (1977). The H number concept. Beckman Technical Bulletin, No. 1095-NUC-77-IT.
Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider R (1995). Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferatin in the p53-negative human prostate cancer cell line PC-3. Cancer Res 55: 2122–2128.
Baldin V, Ducommun B (1995). Subcellular localisation of human weel kinase is regulated during the cell cycle. J Cell Science 108: 2425–2432.
Parker LL, Piwnica-Worms H (1992). Inactivation of the p34cdc2-cyclin B complex by the Human Weel tyrosine kinase. Science 257: 1955–1957.
Shan B, Cahng C-Y, Jones D, Lee W-H (1994). The transcription factor E2F-1 mediates the autoregulation of RB gene expression. Mol Cell Biol 14: 299–309.
Zhu X, Mancini MA, Cahng K-H, et al. (1995). Characterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitoticphase progression. Mol Cell Biol 15: 5017–5029.
Nagel W, Vallee BL (1995). Cell cycle regulation of metallothionein in human colonic cancer cells. Proc Natl Acad Sci 92: 579–583.
Gudas JM, Oka M, Diella F, Trepel J, Cowan KH (1994). Expression of wild-type p53 during the cell cycle in normal human mammary epithelial cells. Cell Growth Diff 5: 295–304.
Coppock DL, Kopman C, Scandalis S, Gilleran S (1993). Preferential gene expression in quiescent human lung fibroblasts. Cell Growth Diff 4: 483–493.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Keyomarsi, K. Synchronization of mammalian cells by Lovastatin. Methods Cell Sci 18, 109–114 (1996). https://doi.org/10.1007/BF00122161
Issue Date:
DOI: https://doi.org/10.1007/BF00122161